Sotorník I, Petrásek R, Schück O, Adamec M, Smrcková I, Tocík J
Klinika kardiovaskulární a transplantacní chirurgie, Praha.
Vnitr Lek. 1997 Sep;43(9):584-91.
Administration of pulse doses of calcitriol is a better way of conservative treatment of secondary hyperparathyroidism (2HPT), making use of the direct suppression of parathormone (PTH) secretion. In a group of 29 haemodialyzed patients the authors evaluated during a six-month follow-up the effect of intravenous Calcijex in 12 and of oral Rocaltrol in 8 subjects. In responders of the calcijex group the PTH level declined by 67.6%, the mean baseline PTH value being 787.8 pg/ml, as compared with non-responders where the decline of PTH at the end of the investigation was 7.5%, the baseline PTH being 1296.4 pg/ml. The difference was significant (p < 0.05). In patients treated with Rocaltrol the therapeutic effect was apparent also in subjects with a lower baseline PTH. An associated phenomenon of treatment are as a rule parallel changes of kALP and ACP levels with those of PTH. It was however revealed that the drop of serum activities can occur also without a concurrent drop of PTH which indicates a dissociation between the level of bone metabolism and PTH secretion. The therapeutic effect can be influenced not only by the stage of 2HPT but also by the route of administration and quantity of calcitriol doses, as ensues from a long-term follow up of one patient. Moreover, the morphological substrate of the hyperplastic tissue of the parathyroid gland and their receptors for 1,25(OH)2D3 must be taken into account. Successfully performed parathyroidectomy, a still justified therapeutic step, is associated as a rule with rapid restoration of PTH levels. TO CONCLUDE: Pulse doses of calcitriol seem to be at present the effective treatment of diagnosed 2HPT, conventional oral calcitriol doses are useful in 2HPT prophylaxis. 2. The i.v. form should be the last resort of conservative treatment before parathyroidectomy. 3. Calcitriol treatment should attempt to maintain slightly raised PTH levels. 4. The limiting indicators of treatment are hypercalcaemia, hyperphosphataemia and the development of extraosseous calcifications. 5. In order to adhere to these criteria it is necessary to use dietary provisions, the dialyzation technique and check biochemical indicators of bone metabolism and possibly change doses of pharmaceutical preparations.
给予冲击剂量的骨化三醇是保守治疗继发性甲状旁腺功能亢进(2HPT)的一种更好方法,它利用了对甲状旁腺激素(PTH)分泌的直接抑制作用。在一组29例血液透析患者中,作者在为期6个月的随访期间评估了12例患者静脉注射盖三淳和8例患者口服罗钙全的效果。在盖三淳组的反应者中,PTH水平下降了67.6%,平均基线PTH值为787.8 pg/ml,而无反应者在研究结束时PTH下降了7.5%,基线PTH为1296.4 pg/ml。差异具有统计学意义(p<0.05)。在接受罗钙全治疗的患者中,治疗效果在基线PTH较低的患者中也很明显。治疗的一个相关现象通常是碱性磷酸酶(kALP)和酸性磷酸酶(ACP)水平与PTH水平平行变化。然而,研究发现血清活性下降也可能在PTH没有同时下降的情况下发生,这表明骨代谢水平与PTH分泌之间存在分离。治疗效果不仅会受到2HPT阶段的影响,还会受到骨化三醇给药途径和剂量的影响,这从对一名患者的长期随访中可以看出。此外,必须考虑甲状旁腺增生组织的形态学基础及其对1,25(OH)2D3的受体。成功进行甲状旁腺切除术这一仍然合理的治疗步骤通常与PTH水平的快速恢复相关。结论:目前,冲击剂量的骨化三醇似乎是已确诊2HPT的有效治疗方法,传统口服骨化三醇剂量对2HPT预防有用。2.静脉注射剂型应是甲状旁腺切除术前保守治疗的最后手段。3.骨化三醇治疗应试图维持PTH水平略有升高。4.治疗的限制指标是高钙血症、高磷血症和骨外钙化的发生。5.为了符合这些标准,有必要采用饮食规定、透析技术并检查骨代谢的生化指标,可能还需要改变药物制剂的剂量。